A “Board and Senior Management Changes” announcement from tissue products manufacturing group Accrol (ACRL) including “it is a statement of how much progress we have made that Accrol is able to attract an operational leader of Mark's capability”. Let’s take a look…
Tissue products manufacturing group Accrol (ACRL) has updated that it received valid applications of 287.64% of the new shares available under an open offer to raise up to £1.935 million at 15p per share. That compares with a 22.5p prior close, but also more than 130p as recently as October 2017, so where now?...
In June 2016 tissue products manufacturer Accrol (ACRL) listed on AIM, raising £63.5 million at 100p per share. Just seventeen months later it was bailout fundraising at half of the IPO price but still recently “revised banking arrangements” have been necessary and now at 3:08pm on 15th May 2018…
In June 2016 tissue products manufacturer Accrol (ACRL) listed on AIM, raising £63.5 million at 100p per share and was “delighted to have received such a high level of interest from institutional investors… we look forward to implementing our strategy and embarking upon this new stage in Accrol's development together”. I most recently updated at 32.5p, concluding this further tale of AIM IPO shame currently remains on the bargepole list. Today a “Trading Update”. It can’t be still worse, surely?...
Writing on Accrol Group (ACRL) previously last month, business and management flux saw me remain sceptical. Now a Board Changes announcement…
Accrol Group (ACRL) has announced results for its half year ended 31st October 2017 including “revenue increased by 13.1% to £72.3m” and “the group remains well placed to benefit from its strong position as a major UK supplier of non-discretionary tissue products into the consumer value sector… Growth in these sectors is being driven primarily by increasing Private Label product sales, which continue to take market share from well-known brands”. Sounds promising…
My previous writing on Accrol Group (ACRL) included also on 17th January the company faces sentencing for a health and safety regulatory offence – for which the Health & Safety Executive is seeking a fine of up to £2.9 million, with a starting point of £1.1 million. There’s now an “Update on Health and Safety Incident”…
Accrol (ACRL) has announced General Meeting refinancing approval – and the shares have responded 5.5% higher to 43p. However, I remind there are still significant reasons for caution here…
With it shares having been suspended in early October “pending clarification of its financial circumstances”, today a “Proposed Placing of £18m and Lifting of Suspension” announcement from Accrol Group (ACRL). Good news then? Well…
Having only been “pleased to announce” it had IPO’d on AIM in June last year, last week saw Accrol Group (ACRL) shares suspended whilst the board considered the anticipated impact on its net debt situation of a now expected “significantly below” expectations earnings performance. This was with “challenging trading conditions” and as it had “recently been advised that a Health and Safety incident, which occurred prior to the company's AIM IPO, may now result in a more significant fine being imposed by the Health and Safety Executive than was previously anticipated”. There is now an “Update on Health and Safety incident” announcement…
Having only been “pleased to announce” it had IPO’d on AIM in June last year, today brings a “Trading Update and Temporary Suspension of Trading” announcement from tissue group Accrol (ACRL). Hmmm…
